Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CPI-0209 · 1 trial · 1 indication
MTD will be determined via Dose-limiting toxicity (DLT)s defined as any grade 3-4 non-hematological or grade 4 hematological toxicity at least possibly related to the treatment, occurring during the first two cycles of treatment and per Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 5.
| Arm | Type | Description |
|---|---|---|
| CPI-0209 (100 mg) + carboplatin | EXPERIMENTAL | CPI-0209: 100 mg (oral dosing) carboplatin administered intravenously as per institutional standards |
| CPI-0209 (150 mg) + carboplatin | EXPERIMENTAL | CPI-0209: 100 mg (oral dosing) carboplatin administered intravenously as per institutional standards |
| Name | Type | Description |
|---|---|---|
| CPI-0209 | DRUG | A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time. |
| carboplatin | DRUG | Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA. |
Inclusion Criteria: * Patients with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer (defined as recurrent disease \> 6 months after completing last platinum- based chemotherapy) that are eligible to receive platinum-based chemotherapy). * Documented disease recurrence/p...
Top 20 of 59 competitors
CPI-0209 is an investigational small molecule being studied for the treatment of recurrent ovarian cancer. It is currently in Phase 1 clinical development, specifically in combination with carboplatin for patients with platinum-sensitive recurrent ovarian cancer.
CPI-0209 is a small molecule in oncology development. Its specific molecular target has not been disclosed in the available clinical trial information. The ongoing trial is evaluating it in combination with carboplatin for recurrent ovarian cancer.
CPI-0209 is being developed by Novartis AG, a global pharmaceutical company listed on the New York Stock Exchange under the ticker NVS. The company is conducting a Phase 1 clinical trial of CPI-0209 in the United States.
CPI-0209 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients with platinum-sensitive recurrent ovarian cancer in the United States.
CPI-0209 is being studied in a single Phase 1 clinical trial with the identifier NCT05942300. The trial, titled 'CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer,' is recruiting 30 female patients aged 18 years and older in the United States.